Based in La Jolla, California, Prediction Sciences develops high-value molecular diagnostics and assays for disease detection, prognosis, and treatment outcome prediction under our trademarked brand names, GeneRx™ and RapidResponse™. 


Prediction Sciences has a deep diagnostics pipeline, with two lead candidates that address critical unmet clinical needs:


  1. GeneRx™ Breast Cancer Profile to determine risk of recurrence in patients with operable breast cancer (available soon from Clarient, Inc. as Insight™ Dx Breast Cancer Profile)

  2. RapidResponse™ c-Fn Test to predict hemorrhagic transformation in stroke patients who are candidates for thrombolytic therapy.


Prediction Sciences is committed to improving the safety and efficacy of disease treatments, and our diagnostic tests are making personalized medicine a reality.